Eli Lilly and Company $LLY Shares Bought by Avaii Wealth Management LLC

Key Points

• Avaii Wealth Management increased its Eli Lilly position by 51.5% in the third quarter, holding 2,522 shares valued at approximately $2.88 million. Institutional investors collectively own 82.53% of the company.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $1,313.43; several firms recently raised their targets.
• Eli Lilly reported strong quarterly results, including $8.38 in earnings per share and $22.97 billion in revenue, up 47.7% year over year. However, executives sold shares under pre-arranged trading plans, and the company faces ongoing litigation and competitive risks.

Avaii Wealth Management LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 51.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,522 shares of the company's stock after acquiring an additional 857 shares during the quarter. Eli Lilly and Company accounts for 0.8% of Avaii Wealth Management LLC's portfolio, making the stock its 27th biggest holding. Avaii Wealth Management LLC's holdings in Eli Lilly and Company were worth $2,883,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of LLY. Bank of America Corp DE purchased a new position in shares of Eli Lilly and Company in the second quarter worth approximately $13,522,666,000. Jupiter Topco LLC bought a new position in Eli Lilly and Company in the second quarter worth approximately $4,667,180,000. Fifth Third Bancorp boosted its stake in shares of Eli Lilly and Company by 321.3% during the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company's stock worth $1,805,959,000 after acquiring an additional 1,497,423 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of Eli Lilly and Company by 353.7% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company's stock valued at $1,425,859,000 after acquiring an additional 1,208,510 shares during the period. Finally, Corient Private Wealth LP bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $764,116,000. Institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of recent research reports. Morgan Stanley raised their target price on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an "overweight" rating in a report on Wednesday. The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a "buy" rating in a report on Thursday, September 17th. Guggenheim lifted their price target on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a "buy" rating in a report on Friday, September 18th. Wall Street Zen lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Sunday, August 23rd. Finally, Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $1,313.43.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: New Phase 3b TOGETHER-PsO data showed that combining Taltz with Zepbound produced broader biological effects than Taltz alone in adults with psoriasis and obesity. By Week 36, the combination changed 482 proteins versus 140 with Taltz alone and affected 467 genes versus 16, alongside improved skin clearance and weight loss. The findings could strengthen Lilly’s case for treating interconnected metabolic and inflammatory conditions. New Phase 3b data on Lilly’s Taltz and Zepbound
• Positive Sentiment: Analyst Cantor Fitzgerald raised its Eli Lilly price target to $1,440 from $1,410 and maintained an Overweight rating, implying meaningful upside based on continued obesity-drug demand and pipeline execution. Cantor Fitzgerald raises pharma price targets
• Positive Sentiment: Recent coverage continues to highlight strong Zepbound demand, potential retatrutide and Foundayo catalysts, and expansion in oncology and Alzheimer’s research. Lilly’s second-quarter revenue growth of roughly 48% and raised outlook provide fundamental support for the long-term growth narrative.
• Neutral Sentiment: Despite its growth profile, Lilly trades below its historical average forward earnings multiple. That may indicate a valuation opportunity, but it also reflects investor concerns about competition, pricing pressure and whether the company’s exceptional growth can continue.
• Neutral Sentiment: Lilly and Nvidia reportedly plan to commit up to $1 billion to an artificial-intelligence drug-discovery laboratory. The initiative may improve future research productivity, although it is unlikely to materially affect near-term earnings. Nvidia and Eli Lilly AI drug-discovery lab
• Negative Sentiment: Lilly’s largest shareholder filed to sell approximately $347 million of stock. The transaction may be routine portfolio management, but its size can raise concerns about insider or major-holder confidence and create additional supply.
• Negative Sentiment: The company is facing a lawsuit from a patient alleging stomach problems linked to Mounjaro and Trulicity. Litigation creates regulatory, legal and reputational risk, although the financial impact remains uncertain.

Insider Buying and Selling

In other news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares of the company's stock, valued at $14,131,250. This trade represents a 29.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Trading Up 0.7%

Shares of LLY stock opened at $1,177.57 on Friday. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $1.11 trillion, a price-to-earnings ratio of 39.52, a price-to-earnings-growth ratio of 1.44 and a beta of 0.46. Eli Lilly and Company has a 12-month low of $783.85 and a 12-month high of $1,292.65. The stock's 50-day moving average price is $1,174.35 and its 200-day moving average price is $1,097.02.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business had revenue of $22.97 billion during the quarter, compared to analysts' expectations of $20.82 billion. During the same quarter last year, the business posted $6.31 EPS. The firm's revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts predict that Eli Lilly and Company will post 36.64 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.